Trial Profile
A retrospective study comparing a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen (BuEM) versus carmustine, etoposide, cytarabine and melphalan (BEAM) for autologous hematopoietic cell transplant in advanced Hodgkin and non-Hodgkin lymphomas.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2016
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Carmustine; Cytarabine
- Indications Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Nov 2016 New trial record